Bolstered by a strong second-quarter, CEO Vas Narasimhan said he expects Novartis to hit the top of its 2018 sales guidance despite joining rival Pfizer in freezing U.S. drug prices for the rest of the year.
Source:: Reuters – Business News
Bolstered by a strong second-quarter, CEO Vas Narasimhan said he expects Novartis to hit the top of its 2018 sales guidance despite joining rival Pfizer in freezing U.S. drug prices for the rest of the year.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.